Search

Search Constraints

You searched for: Author/Creator Cento, V.

Search Results

1. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. (February 2019)

2. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Issue 1 (February 2018)

3. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents. (10th February 2016)

4. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. (15th February 2015)

5. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients. (10th February 2016)

6. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. (17th December 2015)

7. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life. Issue 1 (16th February 2017)

8. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction. (March 2023)

9. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Issue 1 (16th February 2017)

10. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing. Issue 1 (February 2018)